Inhibition of autophagy enhances the antitumour activity of tigecycline in multiple myeloma

Ruye Ma, Yu Zhang, Wei Wang, Junqing Wu, Qianqian Yang, Wanling Xu, Songfu Jiang, Yixiang Han, Yu Kang, Shenghui ZhangJournal of Cellular and Molecular Medicine 2018 · DOI

TL;DR

This study reveals that tigecycline, an antibiotic, effectively inhibits multiple myeloma (MM) cell growth by inducing cell cycle arrest. Crucially, the research demonstrates that autophagy, a cellular self-digestion process, plays a protective role in MM cells treated with tigecycline, and inhibiting autophagy synergistically enhances tigecycline's anti-cancer effects both in vitro and in vivo.

What Problem Does This Paper Address?

Multiple myeloma (MM) remains a challenging hematological malignancy to treat, often characterized by drug resistance and relapse, despite advancements in therapies like proteasome inhibitors and immunomodulatory agents. The authors investigate tigecycline, a glycylcycline antibiotic known for its antibacterial properties, for its potential anti-cancer activity against MM. Specifically, they aim to understand its mechanism of action and explore the role of autophagy in its anti-MM effects, seeking novel therapeutic strategies for this incurable disease.

Methods

The researchers employed a multi-faceted approach to investigate tigecycline's effects on MM cells:

  • Cell Viability and Colony Formation Assays: Standard CCK-8 assays were used to measure cell viability, and soft agar colony formation assays were performed to assess the ability of MM cells to survive and proliferate.
  • Cell Cycle and Apoptosis Analysis: Flow cytometry with propidium iodide (PI) staining was used to analyze cell cycle distribution (G0/G1, S, G2/M phases). Apoptosis was assessed using Annexin V-FITC/PI staining.
  • Western Blot Analysis: This technique was central to examining protein expression and phosphorylation levels of key molecules involved in cell cycle regulation (p21, CDK2, cyclin D1), autophagy (LC3, SQSTM1/p62), and signaling pathways (AMPK, mTOR, Akt, p70S6K1, 4E-BP1).
  • Electron Microscopy: Transmission electron microscopy was used to visualize autophagosomes, providing direct evidence of autophagy induction.
  • In Vivo Xenograft Model: A mouse model was established by implanting RPMI-8226 MM cells into immunocompromised mice. This allowed for the evaluation of tigecycline's anti-tumor efficacy and the synergistic effect of combining tigecycline with an autophagy inhibitor (chloroquine) in a living system.

Datasets

Not discussed in the paper. The study utilized established human MM cell lines (RPMI-8226, NCI-H929, and U266) and NOD/SCID mice for in vivo experiments.

Key Insights and Ideas

  • Tigecycline as an Anti-MM Agent: The study firmly establishes tigecycline as a potent inhibitor of MM cell proliferation and colony formation, moving beyond its known antibacterial role.
  • Cell Cycle Arrest, Not Apoptosis: A key finding is that tigecycline primarily exerts its cytotoxic effect by arresting MM cells in the G0/G1 phase of the cell cycle, rather than inducing apoptosis. This suggests a distinct mechanism of action compared to some other anti-cancer drugs.
  • Autophagy as a Double-Edged Sword (but Protective in this context): While autophagy is often implicated in cancer progression, this study highlights its cytoprotective role in tigecycline-treated MM cells. This is a critical insight, as it suggests that targeting autophagy could be a viable strategy to enhance tigecycline's efficacy.
  • AMPK/mTOR Pathway as the Autophagy Regulator: The research pinpoints the AMPK/mTOR signaling pathway as the key mediator of tigecycline-induced autophagy, with tigecycline enhancing AMPK phosphorylation and subsequently inhibiting mTOR. This provides a molecular explanation for the observed autophagy.
  • Synergistic Effect of Autophagy Inhibition: The combination of tigecycline with autophagy inhibitors (bafilomycin A1 in vitro and chloroquine in vivo) significantly amplified the anti-MM effects, underscoring the therapeutic potential of this combination strategy.

Key Results

  • Tigecycline significantly inhibited the proliferation and colony formation of RPMI-8226, NCI-H929, and U266 MM cell lines in a dose- and time-dependent manner.
  • Tigecycline induced cell cycle arrest at the G0/G1 phase, accompanied by the down-regulation of p21, CDK2, and cyclin D1.
  • Tigecycline induced autophagy in MM cells, evidenced by increased LC3-II accumulation and SQSTM1/p62 degradation, and the presence of autophagosomes.
  • Inhibition of autophagy with bafilomycin A1 (in vitro) or chloroquine (in vivo) significantly enhanced tigecycline's cytotoxicity against MM cells.
  • Tigecycline activated the AMPK pathway and inhibited the mTOR pathway, leading to autophagy.
  • Tigecycline effectively inhibited tumor growth in a mouse xenograft model, and the combination with chloroquine showed a synergistic effect.

Limitations and Future Work

  • Autophagy Mechanism Specificity: While the study demonstrates autophagy induction and its protective role, the precise downstream consequences of this autophagy in MM cells beyond cytoprotection could be further elucidated.
  • Clinical Translation: The study was conducted in cell lines and a mouse model. Further research is needed to assess the safety and efficacy of tigecycline, particularly in combination with autophagy inhibitors, in human clinical trials for MM.
  • Drug Resistance Mechanisms: While tigecycline shows promise, understanding potential resistance mechanisms to this drug and its combination therapy in MM would be valuable for long-term treatment strategies.
  • Broader Application: The study focused on MM. Investigating the role of tigecycline and autophagy in other hematological malignancies or solid tumors could reveal broader therapeutic applications.

Summary updated

Abstract

Accumulating evidence shows that tigecycline, a first-in-class glycylcycline, has potential antitumour properties. Here, we found that tigecycline dramatically inhibited the proliferation of multiple myeloma (MM) cell lines RPMI-8226, NCI-H929 and U266 in a dose and time-dependent manner. Meanwhile, tigecycline also potently impaired the colony formation of these three cell lines. Mechanism analysis found that tigecycline led to cell cycle arrest at G0/G1 with down-regulation of p21, CDK2 and cyclin D1, rather than induced apoptosis, in MM cells. Importantly, we found that tigecycline induced autophagy and an autophagy inhibitor bafilomycin A1 further amplified the tigecycline-induced cytotoxicity, suggesting that autophagy plays a cytoprotective role in tigecycline-treated MM cells. Mechanisms modulating autophagy found that tigecycline enhanced the phosphorylation of AMPK, but did not decrease the phosphorylation of Akt, to inhibit the phosphorylation of mTOR and its two downstream effectors p70S6K1 and 4E-BP1. Tigecycline effectively inhibited tumour growth in the xenograft tumour model of RPMI-8226 cells. Autophagy also occurred in tigecycline-treated tumour xenograft, and autophagy inhibitor chloroquine and tigecycline had a synergistic effect against MM cells in vivo. Thus, our results suggest that tigecycline may be a promising candidate in the treatment of MM.
BibTeX
@article{ma2018inhibition,
  author = {Ruye Ma and Yu Zhang and Wei Wang and Junqing Wu and Qianqian Yang and Wanling Xu and Songfu Jiang and Yixiang Han and Yu Kang and Shenghui Zhang},
  title = {{Inhibition of autophagy enhances the antitumour activity of tigecycline in multiple myeloma}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2018},
  doi = {10.1111/jcmm.13865},
}
Figure